Yuewan Luo

Yuewan Luo is an Academic employee at the Biotech Research & Innovation Centre (BRIC) within the Faculty of Science at the University of Copenhagen, working in the Andersen Group. Based at Ole Maaløes Vej 5 in Copenhagen, Luo maintains an active research profile with expertise spanning cancer immunotherapy, epigenetics, and molecular biology.

Luo completed a Postdoctoral fellowship in Immunology at the University of Florida from September 2019 to October 2020, following a PhD in Epigenetics and Immunology from the Chinese Academy of Science between September 2013 and June 2019. This educational background has established a strong foundation for their current research trajectory.

Research interests focus on therapeutic targets in cancer, particularly through epigenetic mechanisms and omics approaches, with specific emphasis on cholangiocarcinoma. Luo's work demonstrates significant contributions to PROTAC-mediated protein degradation strategies for cancer immunotherapy, as evidenced by multiple high-impact publications in journals including Nature Communications, Molecular Cell, and The Journal of Experimental Medicine. The research portfolio shows a transition from fundamental studies in Drosophila genetics and stem cell biology toward more translational cancer immunology work.

Luo maintains an active research profile with publications receiving attention across multiple platforms, including news outlets, social media (X, Facebook), and academic readership platforms like Mendeley, indicating growing influence in the field of cancer immunotherapy and targeted protein degradation.